• Skip to content
  • skip to navigation
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • What science can do
  • R&D
    • R&D
    • Our approach
    • Transformative science
    • Data science & AI
    • Our technologies
    • Next generation therapeutics
    • Publications
    • R&D strategic centres
  • Our therapy areas
    • All therapy areas
    • Oncology
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Other disease areas
    • Pipeline
    • All medicines
  • Our company
    • Our company
    • Our strategy
    • Our people
    • Our commitment to patients
    • Leadership team
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
  • Investors
    • Investor Relations (Global) UK flag
    • Investor Relations (Sweden) Swedish flag
    • Stock Exchange announcements
    • Results and presentations
    • Annual Reports
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • ADR Programme
  • Media
    • Press Releases
    • Media centre
    • Articles
    • Image library
    • COVID-19 visual resources
    • Broadcast videos
    • Archive
    • Media contacts
  • Sustainability
    • Sustainability
    • Access to healthcare
    • Environmental protection
    • Ethics and transparency
    • Resources
  • Partnering
    • Partnering with AstraZeneca
    • Our Partnering teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Secrets to successful partnering
    • Supplier Information
  • AstraZeneca Websites
  • Global site

R&D / Discovery

08 January 2021

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells

Details

Published:

Cancer Discovery

AstraZeneca author(s):

Simon Dovedi, Yariv Mazor

Related Content:
Dual-action-to-improve-target-specificity

Dual action to improve target specificity

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.




Veeva ID: Z4-25396
Date of next review: August 2022

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • LinkedIn
  • Twitter
  • YouTube
  • Instagram
  • Glassdoor
  • Facebook

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie policy

© AstraZeneca 2021

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue
?

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

I disagree I agree
?
?